Ex vivo drug sensitivity assays have also been performed using retroviral transduction models, identifying BRD2/4 inhibitors, topoisomerase II inhibitors, and gemcitabine as effective in NUP98-KDM5A AML (76). Here, NUP98 is linked to acute myeloid leukemia.